THRβ Agonist Crystal Form for Selectivity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing thyroid hormone receptor agonists face challenges with reduced THRβ biological activity, THRβ/THRα selectivity, and poor stability in vivo, making it difficult to develop effective drugs for metabolic diseases.
Innovation Solution
A new 2-pyridone derivative with high agonist activity and selectivity on thyroid hormone β receptor, formulated in crystalline forms A-F, exhibiting good stability, low hygroscopicity, and minimal heat influence, prepared through specific solvent-based crystallization methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pyridazinone ring structural modifications are made based on MGL-3196, then some pharmacological activity is maintained, but THRβ biological activity and THRβ/THRα selectivity are reduced
Solution Approach 1:
The patent changes the fundamental chemical parameter by replacing the pyridazinone ring with a 2-pyridone ring structure. This structural parameter change restores both high THRβ biological activity (EC50 values in the nanomolar range) and excellent THRβ/THRα selectivity (ratio >100:1), resolving the contradiction between maintaining activity and achieving selectivity that plagues pyridazinone derivatives.
Solution Approach 2:
The patent creates a composite molecular structure combining the 2-pyridone core with specific substituent patterns at positions 4, 5, and 6. This composite structure integrates the pharmacological activity of thyroid hormone analogs with the selectivity-enhancing features of the pyridone scaffold, achieving both high activity and selectivity simultaneously.
2Adaptability or versatility
If nitrogen atom on pyridone is replaced, then structural diversity is increased, but pharmacological activity is lost and stability becomes extremely poor
Solution Approach 1:
The patent applies local quality by maintaining the nitrogen atom at the critical position 1 of the 2-pyridone ring, which is essential for pharmacological activity and metabolic stability. Meanwhile, it allows structural diversity through substituent variations at positions 4, 5, and 6, where the nitrogen is absent. This localized approach preserves activity while enabling structural exploration.
Solution Approach 2:
The patent segments the molecular structure into two functional zones: the nitrogen-containing 2-pyridone core (positions 1-3) that maintains pharmacological activity and stability, and the substituent regions (positions 4-6) that can be varied for structural diversity and property optimization. This segmentation allows independent optimization of different molecular properties.
3Stability of the object's composition
If crystalline forms are prepared through solvent-based crystallization, then stability and low hygroscopicity are achieved, but preparation process complexity increases
Solution Approach 1:
The patent changes the physical parameter of the compound by preparing multiple crystalline forms (Forms A-K) with different lattice structures through controlled solvent crystallization. Each crystalline form exhibits superior stability and low hygroscopicity compared to the amorphous form, while the preparation process uses straightforward solvent-based methods that, although detailed, follow conventional crystallization protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of the 2-pyridone derivative provide enhanced stability and selectivity, enabling effective treatment of metabolic diseases such as obesity, hyperlipidemia, and nonalcoholic steatohepatitis with improved pharmacokinetic properties.
Implementation Method 1
THRβ1 and THRβ2 are obtained by differential expression from promoters, and the two isoforms differ only at the amino terminus. THRα1 and THRα2 result from differential splicing of pre-mRNAs, and mainly differ at the carboxy terminus. THRα1, THRβ1 and THRβ2 can bind to thyroid hormones.
Implementation Method 2
A new 2-pyridone derivative with high agonist activity and selectivity on thyroid hormone β receptor, formulated in crystalline forms A-F, exhibiting good stability, low hygroscopicity, and minimal heat influence
Data Source
AI summary
The present disclosure belongs to the field of medicines. A thyroid hormone β receptor agonist, a crystalline form, a preparation method and the use thereof are provided. The compound is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The X-ray powder diffraction pattern of a crystal form A of the compound of formula (I) comprises characteristic peaks at 6.10±0.20°, 12.08±0.20° and 16.49±0.20° 20, as determined by means of using Cu-Kα radiation. The present invention develops a new 2-pyridone derivative. The compound has high agonistic activity and selectivity for the thyroid hormone β receptor, and can be used for treating metabolic diseases, particularly for treating diseases related to thyroid hormone receptor. The present invention also studies a series of crystal forms of the compound. The crystal form A compound has the advantages of good stability, low hygroscopicity, and small heat influence.